Literature DB >> 20042629

Results of the Abbott RealTime HIV-1 assay for specimens yielding "target not detected" results by the Cobas AmpliPrep/Cobas TaqMan HIV-1 Test.

N Esther Babady1, Jeffrey J Germer, Joseph D C Yao.   

Abstract

No significantly discordant results were observed between the Abbott RealTime HIV-1 assay and the COBAS AmpliPrep/COBAS TaqMan HIV-1 Test (CTM) among 1,190 unique clinical plasma specimens obtained from laboratories located in 40 states representing all nine U.S. geographic regions and previously yielding "target not detected" results by CTM.

Entities:  

Mesh：

Year:  2009        PMID： 20042629      PMCID： PMC2832422          DOI： 10.1128/JCM.01394-09

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  14 in total

1.  Evaluation of the Roche Cobas TaqMan and Abbott RealTime extraction-quantification systems for HIV-1 subtypes.

Authors:  Marie Gueudin; Jean Christophe Plantier; Véronique Lemée; Marie Paule Schmitt; Loic Chartier; Thomas Bourlet; Annick Ruffault; Florence Damond; Muriel Vray; François Simon
Journal:  J Acquir Immune Defic Syndr       Date:  2007-04-15       Impact factor: 3.731

2.  Impaired quantification of plasma HIV-1 RNA with a commercialized real-time PCR assay in a couple of HIV-1-infected individuals.

Authors:  P Colson; C Solas; J Moreau; A Motte; M Henry; C Tamalet
Journal:  J Clin Virol       Date:  2007-05-25       Impact factor: 3.168

3.  HIV-1 viral load blips are of limited clinical significance.

Authors:  Patricia K Lee; Tara L Kieffer; Robert F Siliciano; Richard E Nettles
Journal:  J Antimicrob Chemother       Date:  2006-03-13       Impact factor: 5.790

4.  Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART.

Authors:  Richard E Nettles; Tara L Kieffer; Patty Kwon; Daphne Monie; Yefei Han; Teresa Parsons; Joseph Cofrancesco; Joel E Gallant; Thomas C Quinn; Brooks Jackson; Charles Flexner; Kathryn Carson; Stuart Ray; Deborah Persaud; Robert F Siliciano
Journal:  JAMA       Date:  2005-02-16       Impact factor: 56.272

5.  HIV-1 group O virus identified for the first time in the United States.

Authors:  M A Rayfield; P Sullivan; C I Bandea; L Britvan; R A Otten; C P Pau; D Pieniazek; S Subbarao; P Simon; C A Schable; A C Wright; J Ward; G Schochetman
Journal:  Emerg Infect Dis       Date:  1996 Jul-Sep       Impact factor: 6.883

6.  HIV-1 subtype diversity in Minnesota.

Authors:  Tracy L Sides; Omobosola Akinsete; Keith Henry; Jason T Wotton; Peter W Carr; Joanne Bartkus
Journal:  J Infect Dis       Date:  2005-05-27       Impact factor: 5.226

7.  Human immunodeficiency virus type 1 (HIV-1) plasma load discrepancies between the Roche COBAS AMPLICOR HIV-1 MONITOR Version 1.5 and the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 assays.

Authors:  F Damond; B Roquebert; A Bénard; G Collin; M Miceli; P Yéni; F Brun-Vezinet; D Descamps
Journal:  J Clin Microbiol       Date:  2007-08-22       Impact factor: 5.948

8.  Comparison of the Roche COBAS Amplicor Monitor, Roche COBAS Ampliprep/COBAS Taqman and Abbott RealTime Test assays for quantification of hepatitis C virus and HIV RNA.

Authors:  Dietmar Wolff; Andreas Gerritzen
Journal:  Clin Chem Lab Med       Date:  2007       Impact factor: 3.694

9.  Infection with HIV type 1 group M non-B subtypes in individuals living in New York City.

Authors:  Jacqueline M Achkar; Sherri T Burda; Frank A J Konings; Mateusz M Urbanski; Constance A U Williams; Dorothee Seifen; Martha N Kahirimbanyi; Mary Vogler; Mark Parta; Helene C Lupatkin; Susan Zolla-Pazner; Phillipe N Nyambi
Journal:  J Acquir Immune Defic Syndr       Date:  2004-07-01       Impact factor: 3.731

10.  The significance of low-level plasma HIV viral load on COBAS TaqMan HIV-1 assays for patients with undetectable plasma viral load on COBAS Amplicor monitor version 1.5.

Authors:  Kaveh Manavi
Journal:  HIV Clin Trials       Date:  2008 Jul-Aug
View more
  1 in total

1.  Increased risk of virologic rebound in patients on antiviral therapy with a detectable HIV load <48 copies/mL.

Authors:  Timothy J Henrich; Brian R Wood; Daniel R Kuritzkes
Journal:  PLoS One       Date:  2012-11-15       Impact factor: 3.240
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.